Format

Send to

Choose Destination
Autoimmunity. 2018 Dec;51(8):408-416. doi: 10.1080/08916934.2018.1547711. Epub 2019 Jan 2.

Islet autoantibody positivity in overweight and obese adults with type 2 diabetes.

Author information

1
a Department of Medicine, Division of General Internal Medicine , The Johns Hopkins University School of Medicine, Baltimore , MD , USA.
2
b Baylor College of Medicine , Houston , TX , USA.
3
c National Institute of Diabetes and Digestive and Kidney Diseases , Phoenix , AZ , USA.
4
d Department of Epidemiology , The Johns Hopkins Bloomberg School of Public Health , Baltimore , MD , USA.
5
e Massachusetts General Hospital and Harvard Medical School , Boston , MA , USA.
6
f Columbia University Medical Center , New York , NY , USA.

Abstract

Islet autoantibodies are typically associated with type 1 diabetes, but have been found in patients diagnosed with type 2 diabetes in whom they are associated with lower adiposity. The significance of autoantibody positivity in overweight and obese patients is not well understood. The aim of this study was to determine the prevalence and clinical significance of islet autoantibodies in overweight/obese adults diagnosed with type 2 diabetes. This study includes 204 participants at one site of the multicenter Look AHEAD (Action for Health in Diabetes) trial (ClinicalTrials.gov identifier: NCT00017953) which randomized overweight/obese adults diagnosed with type 2 diabetes to an intensive lifestyle intervention or diabetes support and education. We measured antibodies to glutamic acid decarboxylase, insulinoma antigen-2, and zinc transporter 8. Participants with and without autoantibodies were compared with respect to baseline clinical features, and longitudinal changes in weight, hemoglobin A1c, and antihyperglycemic medications. We found that 13 participants (6.4%) were autoantibody positive, including six of 47 participants (12.8%) with BMI ≥40 kg/m2. At baseline, autoantibody positive participants had higher HDL cholesterol (1.27 vs. 1.09 mmol/L, p = .034) and lower fasting C-peptide (0.32 vs. 0.57 nmol/L, p = .049). Over four years, autoantibody positive participants lost 5.1 kg more weight than autoantibody negative participants (p = .056). Longitudinal changes in hemoglobin A1c did not differ by autoantibody status, though autoantibody positive participants were more likely to increase the number of antihyperglycemic medications or initiate insulin (p = .011). In conclusion, islet autoantibodies were present in 6.4% of overweight/obese adults with type 2 diabetes including those with severe obesity, and were associated with distinct clinical features. The effect of autoantibody positivity on weight loss interventions requires further study.

KEYWORDS:

Type 2 diabetes; autoantibodies; autoimmunity; islet cell antibody; obesity; weight loss

PMID:
30661481
PMCID:
PMC6362362
[Available on 2020-01-02]
DOI:
10.1080/08916934.2018.1547711

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center